Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma

Topics

neoadjuvant immunotherapy · nivolumab · ipilimumab · resectable stage III melanoma · macroscopic stage III melanoma · event-free survival · adjuvant immunotherapy · major pathological response · pathological complete response · partial response · Non-response · recurrence-free survival · residual viable tumor · restricted mean survival time · response-driven adjuvant therapy · immune checkpoint inhibitors · surgical resection timing · treatment-related adverse events